# EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

> **NCT00821717** · PHASE3 · TERMINATED · sponsor: **Vifor Pharma** · enrollment: 35 (actual)

## Conditions studied

- Chronic Heart Failure
- Iron Deficiency
- Iron Deficiency Anemia
- Anaemia

## Interventions

- **DRUG:** Ferinject ® (Ferric carboxymaltose)
- **DRUG:** Normal saline (0.9%)

## Key facts

- **NCT ID:** NCT00821717
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2009-10
- **Final completion:** 2011-01
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Positive FAIR-HF study data are available, this study is identical as EFFICACY-HF. Due to low recruitment in EFFICACY-HF the decision was made to terminate it.
- **Last updated:** 2015-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821717, "EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00821717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*